Novelion Therapeutics (TSX:NVLN) Dividend Payout Ratio : 0.00 (As of Mar. 2019)

View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Dividend Payout Ratio?

Novelion Therapeutics's dividend payout ratio for the months ended in Mar. 2019 was 0.00.

The historical rank and industry rank for Novelion Therapeutics's Dividend Payout Ratio or its related term are showing as below:

TSX:NVLN's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-10), the Dividend Yield % of Novelion Therapeutics is 0.00%.

Novelion Therapeutics's Dividends per Share for the months ended in Mar. 2019 was C$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Novelion Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for Novelion Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Dividend Payout Ratio Chart

Novelion Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dividend Payout Ratio

Get a 7-Day Free Trial

Novelion Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Novelion Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, Novelion Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Dividend Payout Ratio falls into.

Novelion Therapeutics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Novelion Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2018 )	/	EPS without NRI (A: Dec. 2018 )
	=	0	/	0
	=	N/A

Novelion Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2019 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2019 )	/	EPS without NRI (Q: Mar. 2019 )
	=	0	/	0
	=	N/A

Novelion Therapeutics (TSX:NVLN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Novelion Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (TSX:NVLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (TSX:NVLN) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3

Website

http://www.novelion.com

Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Novelion Therapeutics (TSX:NVLN) Headlines

No Headlines